Tag: M.D. Anderson Cancer Center
Lexicon Pharmaceuticals, Inc. Clinical Trial Recruiting Carcinoid Syndrome Patients
September 10, 2010
Patients with carcinoid syndrome, whose symptoms are not managed by octreotide therapy, are being recruited for a Phase 2 clinical trial of Lexicon Pharmaceuticals’ LX1606 (a.k.a. LX1032). The trial has been given Fast Track status in the U.S. and …
READ MORE
FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
August 24, 2010
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MORECarcinoid Syndrome Clinical Trial to Be Featured on Webcast
April 6, 2010
Lexicon Pharmaceuticals’ clinical trial LX1032 for carcinoid syndrome will be among the clinical programs that are reviewed in-depth on April 8, 2010 when the company holds its Annual R&D Day from 7:30 to 11:00 am, Eastern Time, in New York City. …
READ MORE
